Kidney Disease, Strategic Development


PDL BioPharma Inc

in
#1  PDL BioPharma Inc. said it will stop pursuing the sale of the company or its biotechnology assets after a firm offer failed to emerge, sending its shares down nearly 19% in extended trading. The company said it now plans to cut 260 jobs and restructure to focus on discovery and development of antibody-based drugs.

Genzyme Corp.

in
Genzyme Corp. announced the U.S. launch of the phosphate binder Renvela(R) (sevelamer carbonate) for dialysis patients, as well as significant progress in its international efforts to secure additional approvals for the product. Genzyme has submitted a marketing authorization application to the European Medicines Agency seeking approval of Renvela for the control of serum phosphorus in chronic kidney disease patients regardless of whether they are on dialysis.

Fresenius Medical Care AG & Co. KGAA

in
Fresenius Medical Care AG & Co. KGAA is expanding the capacity for producing dialysis products at its plant in St. Wendel, Germany. The Company will invest a total of approximately EUR 39 million over the next 12 months. About EUR 23 million will be invested in an additional building and two new spinning lines for hollow fibers, the key component of dialyzers (artificial kidneys).

Para Membranes has entered into an exclusive strategic distribution

in
Para Membranes has entered into an exclusive strategic distribution relationship with PRISMEDICAL Corporation for sales of Para Membranes' patented HFM products.
 

Gambro AB

in
Gambro AB announced the start of a strategic alliance with Sandoz, Inc. Both companies have agreed to cooperate in the launch of Sandoz' biosimilar Binocrit, the first biosimilar epoetin alfa which has been approved by the European Commission in August this year.

Renal Solutions

in
US company Renal Solutions has selected Sabic Innovative Plastics’ improved haemo-compatibility Lexan HPM grade of polycarbonate to produce its Pulsar blood pump, which lies at the core of its Allient Sorbent Haemodialysis System. More.

Dubai International Capital

in
Dubai International Capital (DIC) and private-equity firm Bridgepoint plan to bid jointly for healthcare group Euromedic International for about 700 million pounds ($1.4 billion), the London Times said on Sunday. More.
 

Isotechnika Inc

in
Isotechnika Inc. announced that the International Nonproprietary Name (INN) expert committee has accepted the proposed generic name of its lead immunosuppressive drug, ISA247. ISA247 will now be referred to as voclosporin. The name will serve to identify the active pharmaceutical substance during the drugs' life-time worldwide.

Cantel Medical Corp. and the National Safety Council (NSC)

in
Cantel Medical Corp. and the National Safety Council (NSC) announced a joint marketing and distribution agreement to help businesses and other organizations prepare for the threat of a flu pandemic and similar infectious diseases. The World Health Organization continues to track the incidence of avian bird flu throughout the world and warns of the potential of mutation of the H5N1 virus that could result in a widespread human-to-human pandemic.

B. Braun Medical Inc.

in
B. Braun Medical Inc. announced update on the recall of contaminated lots of heparin products from company and the ongoing testing of the heparin supply in Canada. The presence of a contaminant in the active pharmaceutical ingredients of certain lots of B. Braun heparin products was first identified by Health Canada and communicated to Canadians on March 20, 2008.

123next ›last »
Syndicate content